Skip to main content
Download PDF

Role of MAML1 in targeted therapy against the esophageal cancer stem cells

Journal of Translational Medicine volume 17, Article number: 126 (2019) Cite this article

Abstract

Background

Esophageal cancer is the sixth-leading cause of cancer-related deaths worldwide. Cancer stem cells (CSCs) are the main reason for tumor relapse in esophageal squamous cell carcinoma (ESCC). The NOTCH pathway is important in preservation of CSCs, therefore it is possible to target such cells by targeting MAML1 as the main component of the NOTCH transcription machinery.

Methods

In present study we isolated the CD44+ ESCC CSCs and designed a MAML1-targeted therapy to inhibit the NOTCH signaling pathway. CSCs were isolated using magnetic cell sorting utilizing the CD44 cell surface marker. Several stem cell markers were analyzed in the levels of protein and mRNA expression. The isolated CSCs were characterized in vivo in NUDE mice. Biological role of MAML1 was assessed in isolated CD44+ CSCs. A drug resistance assay was also performed to assess the role of MAML1 in CD44+ CSCs with 5FU resistance.

Results

The CD44+ CSCs had ability to form tumors in NUDE mice. MAML1 silencing caused a significant decrease (p = 0.019) and ectopic expression caused a significant increase in migration of CD44+ CSCs (p = 0.012). Moreover, MAML1 silencing and ectopic expression significantly increased and decreased 5FU resistance, respectively (p < 0.05). MAML1 silencing significantly increased the number of cells in G1 phase (p = 0.008), and its ectopic expression significantly increased the number of CD44+ CSCS in S phase (p = 0.037).

Conclusions

MAML1 may be utilized for targeted therapy with a low side effect to eliminate the CD44+ CSCs through inhibition of canonical NOTCH pathway in ESCC patients.

Background

Esophageal cancer (EC) is the sixth-leading cause of cancer related deaths worldwide [1, 2]. There are two histopathological EC subtypes; esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC). Patients with either subtype receive the same treatment, which is a neo adjuvant chemo-radiotherapy (nCRT) before the surgery. A heterogeneous response occurs to nCRT; approximately 75% of EAC patients will not achieve a pathological complete response [3]. Apart from new progresses in therapeutic modalities, ESCC patients have poor prognoses due to chemo and radiation therapy resistance. The 5-year survival rate after surgery is 20–40% [4]. Although, specific multimodal treatments increase the 5-year survival [3], 60–70% of patients do not respond to these treatments [5]. Cancer stem cells have been proposed as important factors in resistance to the multimodal treatments [6, 7]. Cancer stem cells have been shown to have several specific characteristics including drug resistance, self-renewal, and tumorigenicity [8]. They can be identified using intracellular and cell surface markers [8]. CD44 is an integral membrane glycoprotein that binds to hyaluronic acid and is involved in tumor growth and metastasis [9]. CD44 is one of the main cell surface candidates in cancer stem cells detection and isolation [10]. Recent work has shown that CD44 is involved in self-renewal and contributes to reactive oxygen species (ROS) depletion by up regulation of glutathione as an important antioxidant [11]. CD44 has been introduced as one of the main cell surface markers in epithelial CSCs [11, 12]. Some CD44+ CSCs have epithelial–mesenchymal transition (EMT) ability, and contribute to tumor progression and metastasis [13, 14]. NOTCH signaling is involved in self-renewal and cell fate through diverse processes including vascular development, hematopoiesis, and neurogenesis [15]. NOTCH is a critical signaling pathway involved in CSC regulation [16]. This range of functions is related to the ability of NOTCH pathway to regulate cell proliferation, apoptosis, and differentiation [17]. Four NOTCH receptors (Notch1-4) and six ligands (Jagged1-2, Delta1, and Delta-like 1-4) are presented in mammalian cells. Receptor–ligand interactions between adjacent cells trigger the NOTCH pathway via at least two proteolytic cleavages at S2 and S3 sites of NOTCH receptor. These cleavages are mediated by ADAM metalloprotease and gamma secretase activity to release the intracellular domain of NOTCH (ICN) [18]. ICN migrates to the nucleus and binds to CSL family of DNA-binding transcription factors. Subsequently, CSL activation is done by substitution of transcriptional co-repressors, including CIR [19], SMRT/N-CoR [20], and KyoT2 [21], and recruitment of co-activators, including CBP/p300 [22] and mastermind-like proteins (MAML) [23]. The multiprotein complex comprising MAML1, CSL, and ICN activates transcription of NOTCH target genes following the activation of NOTCH receptors [24]. HES and HEY proteins are the main targets of the NOTCH pathway and act as transcriptional repressors through their basic helix-loop-helix and WRPW domains to regulate several genes including cyclin D1 [25], NF-κB [26], p21 [17], MYC [27], and SLUG [28]. Despite the pivotal role of the NOTCH pathway in tissue homeostasis, over-activation of stem cell pathways can result in malignant cells. The NOTCH pathway increases tumor survival by maintaining CSCs and is involved in chemotherapeutic resistance and EMT. Generally, targeting the NOTCH pathway can be effective in limiting tumor recurrence. In this study, we hypothesized that the CSCs may be the main reason for chemo-radio therapeutic resistance in ESCC patients. Cancer stem cells were isolated and characterized from an ESCC patient and the role of MAML1 as the main component of the NOTCH pathway was assessed in the biology of isolated ESCC-CSCs for the first time.

Methods

Cell culture and sphere formation

Fresh tissue was obtained from an 84-year old male ESCC patient who was undergone an esophagectomy before chemo-radio therapy. Informed consent form which was approved by the ethic committee was filled by the patient. The sample was minced into 1 mm pieces and transferred to D-Hank’s buffer containing collagenase type I (0.25 mg/ml; Worthington Biomedical Corporation) and incubated at 37 °C for 3 h. Single cells were cultured in a specific complete medium comprising DMEM/F12 supplemented with penicillin/streptomycin (10 units/ml), insulin (25 µg/ml), epidermal growth factor (EGF, 20 ng/ml), and basic fibroblast growth factor (bFGF, 10 ng/ml) in a humidified atmosphere containing 5% CO2 at 37 °C. For tumor sphere formation, cancer cells were cultured for 3 weeks in low attachment plates.

RNA isolation and real-time PCR

Total RNA was extracted using Trizol according to the manufacturer’s instructions. cDNA synthesis was performed using the First-Strand Synthesis kit (Fermentas, Lithuania). Subsequently, comparative relative real-time PCR was performed in triplicate reactions using SYBR Green (GENETBIO, Korea) by a Stratagene Mx3000P real-time thermocycler (Stratagene, La Jolla, CA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a normalizer (Table 1). Greater than twofold decreases or increases in mRNA expression were considered as under- and over-expression, respectively.

Table 1 Primer sequences for the real time PCR
Full size table

In vivo tumorigenicity assay

Six-week-old male nude mice (NUDE) were used in this study. Four million tumor cells derived from the ESCC spheres were mixed with Matrigel (2:1, volume), and mice were injected subcutaneously. Tumor growth was monitored weekly and measured using a caliper.

Western blot, H&E staining, and immunohistochemistry of xenografts and primary tumors

Proteins were extracted with RIPA buffer, separated on 10% SDS-PAGE, transferred to membranes (Millipore, Bedford, MA), and immunoblotted with specific antibodies. The explanted tumor was embedded in paraffin and cut into 4 mm sections using a microtome. Sections were de-paraffinized using Roticlear (Carl Roth, Germany) and hydrated in an ethanol series. Antigens were retrieved by heating the samples in 10 mM citrate buffer. The samples were blocked and then incubated at 4 °C for 16 h with the primary antibodies: anti-P63 (1:1000, BD Biosciences), anti-cytokeratin 18 (1:500, DakoCytomation), anti-cytokeratin 19 (1:500, Miltenyi Biotech), anti-CD117 (1:2000, Dako), or anti-CD44 (1:1000, Dako), and then with secondary antibody.

Immunocytochemistry

Cells (106 cells per slide) were plated and cultured for 24 h on sterile slides. The slides were washed three times with phosphate-buffered saline (PBS, 0.01 M, pH 7.4), and fixed in 4% formaldehyde for 10 min at room temperature, and incubated in 3% hydrogen peroxide for 10 min. Slides were incubated with anti-p63 antibody (1:500, Abcam), anti-cytokeratin 18 (1:500, Novocastra), and anti-CD44 (1:1000, Dako) overnight at 4 °C. Finally, the slides were incubated with secondary antibodies for 30 min at 37 °C and visualized with diaminobenzidine.

Cell cycle analysis

CD44+ CSCs were plated and transfected in 24 wells plates. The transfected cells were trypsinized and mixed with propidium iodide (PI, 50 µg/ml) and RNaseA (100 µg/ml) and incubated at 4 °C for 60 min. The cells were washed with PBS to eliminate the extra PI. Finally, a suspension of 300,000 cells/ml was prepared to detect cell cycle distribution using flow cytometry (Franklin Lakes, USA). The cell cycle was analyzed using Mod Fit LT (version 4.1) software.

Plasmids and transfection

Human full-length MAML1 cDNA was sub-cloned into the CMV2-pFLAG vector (a generous gift from Dr. Lizi Wu, University of Florida). CD44+ CSCs were transfected with X-treme GENE HP (Roche, Germany) according to the manufacturer’s instructions. Cells were also transfected with pLKO vector, harboring MAML1 short hairpin RNA for 24 h (MAML1 shRNA-1790). ShRNA encoding target sequences to MAML1 mRNA was designed by the primer sequences as follows: 5′-CCGGTCCGGGCTGGACTACGGCAATACAAACTCGAGTTTGTATTGCCGTAGTCCAGCTTTTT-3′ and 5′-AATTCAAAAAGCTGGACTACGGCAATACAAACTCGAGTTTGTATTGCCGTAGTCCAGCCCGG-3′.

Drug resistance assay

CD44+ CSCs cells were transfected with the MAML1-CMV2-pFLAG and MAML1-pLKO vectors using X-treme GENE transfection reagent. Cells were exposed to varying concentrations of 5FU (10−2 µm/l to 103 µm/l), treated with 50 µl of 5 mg/ml of dimethyl thiazolyldiphenyltetrazolium (MTT) dye (Sigma; Dorset) and incubated for 4 h at 37 °C. The plates were quantified at an absorbance of 570 nm. All assays were repeated three times with 10 replicates.

Migration assay

Cells were cultured in specific serum-free medium in 6-well plates and grown to achieve 70% of confluence. The medium was replaced 24 h after transfection. After 10 days, the cells were scratched with a p200 pipette tip and free detached cells were removed with PBS. Plates were monitored for 15 days in 5 days intervals. The cell-free area was measured using a 10× objective (OPTIKA, Italy). Non transfected cells were used as control to assess the migration of transfected cells. All assays were performed in triplicates and significant changes among transfected and non-transfected cells were assessed by ANOVA test.

Results

Characterization of isolated CD44+ CSCs

Sphere formation

The first step in characterization of isolated CSCs was tumor sphere formation in specific medium. After the enzymatic digestion, cells were cultured in specific medium in low adherent flasks, which inhibit fibroblast overgrowth. The first CD44+ tumor sphere was observed after 10 days (Fig. 1A). Spheres were able to adhere and differentiate in the flasks (Fig. 1B, C).

Fig. 1
figure1

Sphere formation and differentiation. The first CD44+ tumor sphere was observed after 10 days (low adherent flasks) (A). Spheres were able to adhere and differentiate in the adherent flasks (B, C)

Full size image

CD44+ CSC enrichment and NUDE mice injection

A major factor in characterization of CSCs is tumor generation in NUDE mice. Cancer stem cell biomarkers were characterized using immunocytochemistry for P63, CD44, and CK18. The CSCs expressed all these markers, indicating they were of esophageal origin (Fig. 2A–C). The CD44+ CSCs were cultured in low-adherent plates and four million cells were injected into the mice using Matrigel. We first observed the tumor after 12 days, and allowed it to grow for 45 days. The tumor was 1.4 by 1 mm after the resection (Fig. 2D).

Fig. 2
figure2

Immunocytochemistry was performed before the mice injection to ensure about the characteristics of isolated cells. The cells were positive for the CK18 as one of the main epithelial markers (A). The cells were also positive in the case of P63 expression as the well know esophageal marker (B). Finally, it was shown that the cells had CD44 expression, approving the isolation process based on CD44 (C). In vivo assay was done using the CD44+ CSCs injection to the nude mice. Mice were sacrificed and tumor was resected after 45 days (1.4 cm) (D)

Full size image

Expressional analysis of stem cell markers

To ensure that the CD44+ CSCs have stem cell features, we analyzed mRNA expression and compared it to CD44− cells as the control. Compared to the control cells, the CD44+-enriched CSCs had NANOG, SOX2, and OCT4 over expression. Moreover, the isolated CD44+ cells had SALL4, DPPA2, CD44V3, CD44V6, CD44S, and BMI1 over expression. These results approved the efficiency of our isolation procedure for CD44+ CSCs. Finally, we tested the expression of NOTCH components in the CD44+ enriched cells. MAML1 and NOTCH target genes (HES1, HEY1, and HEY2) were over expressed. Expression of PYGO2 as an important component of the WNT signaling pathway was normal. This showed that the WNT pathway probably has no significant role in the biology of CD44+ enriched cells. DPPA2 and PYGO2 had the highest and lowest levels of mRNA expression with 13.8- and 1.03-fold changes, respectively (Fig. 3).

Fig. 3
figure3

Expressional analysis of stem cell markers. Compared to the control cells (CD44−), the CD44+-enriched CSCs overexpressed NANOG, SOX2, and OCT4. Moreover, the isolated CD44+ cells overexpressed SALL4, DPPA2, and BMI1. Additionally, CD44V3, CD44V6, and CD44S, three CD44 isoforms were overexpressed in these CSCs. MAML1 a major factor in the transcription mechanism, and the NOTCH target genes HES1, HEY1, and HEY2 were overexpressed. Expression of PYGO2, a major component of the WNT transcription mechanism, was normal

Full size image

Expressional analysis after the NUDE mice tumor resection

After the resection, tumor tissue was evaluated to determine the ratio of cancer/normal cells by H&E staining. Protein expression was analyzed for P63, CD44, CK18, CK19, and SOX2 using immunohistochemistry (Fig. 4A–D). Moreover, NANOG and OCT4 expression were analyzed by western blot (Table 2) (Fig. 4E). These results indicated that the generated tumor in nude mice was ESCC with a self-renewal behavior.

Fig. 4
figure4

Expressional analysis after the NUDE mice tumor resection. Expression of CD44 in the resected tumor from the nude mice (A). Representative IHC analyses of CK18 in ESCC tissues (B). Strong expression of P63 (C). SOX2 expression (D). NANOG and OCT4 protein expression were analyzed using the western blot in ESCC tumor which was resected from the nude mice (E)

Full size image
Table 2 Antibodies for western blot
Full size table

Role of MAML1 in biology of CD44+ CSCs

Transfection and expressional analysis

In the present study we assessed the probable role of MAML1 in the preservation of CD44+ CSCs. Therefore, MAML1, as the main component of the NOTCH transcription machinery, was targeted by ectopic expression and silencing. MAML1 mRNA expression was evaluated after the ectopic expression and silencing with real time PCR. MAML1 mRNA expression in CD44+ transfected cells was compared to that of the CD44+ non transfected cells. MAML1 expression was 6.71-fold greater and 3.04-fold less in ectopically-expressed and silenced CD44+ CSCs, respectively. Moreover, to assess the expected change in MAML1 function, mRNA expression of HEY1, HEY2, and HES1 as the main targets of the NOTCH pathway were also assessed after the transfection (Fig. 5).

Fig. 5
figure5

Expression analysis of NOTCH target genes in the level of mRNA expression after the transfection approved the efficiency of transfection. Red shows the fold changes after ectopic expression and blue represents the fold changes following the silencing

Full size image

Migration assay

One of the most important features of the CSCs is their ability to migrate and cause metastasis via EMT. To assess this, a scratch assay was performed to analyze the probable role of the NOTCH pathway in the regulation of cell migration. The results showed that CSC migration increased significantly after the MAML1 ectopic expression (p = 0.012). Migration of CSCs decreased after the MAML1 silencing (p = 0.019) (Figs. 6, 7). Two involved factors in the EMT process are Twist and Snail. We previously showed that MAML1 and Twist1 expression in ESCC patients is significantly correlated with EMT [29]. Twist1 expression was also assessed after the migration assay in transfected cells. Interestingly, Twist1 expression decreased 2.18-fold and increased 2.59-fold in silenced and ectopically expressed cells, respectively, relative to the non-transfected cells. Therefore, similar to the recent report regarding the role of MAML1/TWIST1 in EMT in ESCC patients, such markers are also involved in EMT of CD44+ CSCs.

Fig. 6
figure6

Migration assay was performed in transfected and non-transfected CD44+ CSCs. The cells were monitored in 5 days intervals (×10 objective; OPTIKA, Italy)

Full size image
Fig. 7
figure7

There was a significant increase and decrease in cell migration after the MAML1 ectopic expression and silencing, respectively

Full size image

Drug resistance

In addition to self-renewal and EMT, resistance to chemotherapy is another feature of CSCs. Therefore, after the migration assay, we performed an MTT assay to assess the probable role of NOTCH in CD44+ CSCs drug resistance. Cancer stem cells were treated with serial dilutions of 5FU for 5 days. Resistance toward the 5FU decreased significantly in silenced CD44+ CSCs compared with the non-transfected CD44+ CSCs (5.478 µm/l vs. 8.395 µm/l, IC50) (p ≤ 0.005). MAML1 ectopic expression also increased the 5FU resistance in CD44+ transfected cells in comparison with non-transfected CD44+ CSCs (14.1 µm/l vs. 8.395 µm/l, IC50) (p ≤ 0.005) (Fig. 8). It has been shown that the ABC transporters are the main factors in drug resistance. We selected ABCG2 and ABCC4 to find the probable factors involved in 5FU resistance. MAML1 ectopic expression and silencing directly correlated with ABCG2 mRNA expression. Levels of ABCG2 mRNA in MAML1 silenced and ectopic expressed cells were − 3.72 and 2.56-fold changes respectively in comparison with the none transfected CSCs. Therefore, ABCG2 is an important factor in 5FU resistance in CD44+ CSCs, which is regulated by the NOTCH pathway in such cells.

Fig. 8
figure8

Drug resistance. Resistance toward the 5FU decreased significantly in silenced CD44+ CSCs compared with the non-transfected CD44+ CSCs. MAML1 ectopic expression also increased the 5FU resistance in CD44+ transfected cells in comparison with non-transfected CD44+ CSCs

Full size image

Role of MAML1 in cell cycle regulation

Cell cycle analysis using the PI flowcytometry was performed to assess and compare the percentage of transfected cells to non-transfected cells. After transfection with MAML1 shRNA, CD44+ CSCs significantly accumulated at G1 phase, with a concomitant reduction in S phase (p = 0.008). Following the MAML1 silencing, number of accumulated cells in G1 phase increased 10% and number of cells in S phase decreased 6.85%. In contrast with the silencing, MAML1 ectopic expression significantly increased number of cells in S phase and decreased number of cells in G1 phase with 7.36% and 12.01%, respectively (p = 0.037) (Fig. 9). The results showed that the NOTCH signaling pathway is not only involved in drug resistance and cell migration, but also is involved in cell cycle regulation of CD44+ CSCs.

Fig. 9
figure9

Role of MAML1 in cell cycle regulation. Cell cycle analysis using the PI flow cytometry was performed to assess and compare the percentage of transfected cells to non-transfected cells. Non transfected CSCs (a). MAML1 shRNA significantly increased cells in G1 phase, with a concomitant reduction in S phase (b). In contrast, MAML1 ectopic expression significantly increased number of cells in S phase and decreased number of cells in G1 phase (c)

Full size image

Discussion

Clear differences in ESCC prevalence are responsible for the “Asian esophageal cancer belt”, which includes parts of China and northern Iran. Esophageal cancer in northeast of Iran is 20 times more prevalent than the other areas [30]. Cancer stem cells were first identified in leukemia, and subsequently found in solid tumors including breast, colon, prostate, liver, and melanoma [31,32,33]. Differentiation therapy is a well-known method to eliminate the CSCs. All-trans retinoic acid (ATRA) is one the most common differentiation therapies used to treat leukemia [34]; however, it has been shown that in addition to CSCs, ATRA stimulates normal esophageal stem cells to differentiate, leading to side effects [35, 36]. Generally, such drugs target all proliferative cells and their usage results in side effects that include weight loss, blood pressure changes, diarrhea, and heart arrhythmias. ESCC-CSCs were identified for the first time using CD44 [10]. CD44 is a universal CSC marker for various solid tumors. We previously showed a significant correlation between CD44 expression and tumor grade and depth of invasion [37]. However, CD44 expression is also observed in the basal layer of normal esophagus, which is the main location for normal esophageal stem cells [38, 39]. In this study we showed that only CD44+ CSCs are able to form tumors in NUDE mice. Moreover, these cells were more resistant to 5FU in comparison with the CD44− tumor cells. Our results indicate that the isolated CD44 cells were the CSCs. To narrow the spectrum of target cells in ESCC therapy we targeted the ESCC-CSCs via the MAML1 as the main component of the NOTCH transcription machinery. Other studies have targeted NOTCH; however, those used gamma secretase inhibitors to block ICN release inside the cytoplasm [40, 41]. Gamma secretase inhibitors also have undesirable side effects [42]; therefore, NOTCH inhibition by gamma secretase may not be an efficient method for the elimination of ESCC-CSCs. Such inhibitors target both normal and cancer stem cells. In a more precise method of targeted therapy the NOTCH receptors were targeted by specific antibodies. Targeted therapy against the NOTCH1 receptor in T-ALL resulted in fewer undesirable side effects than the gamma secretase inhibitors [43]. However, using specific antibodies also influenced the function of somatic stem cells in the basal layer [44]. Therefore, we aimed to target the CSCs with no undesirable effect on normal stem cells. Most of the recent studies targeted the NOTCH pathway at membrane receptors; however, the NOTCH pathway operates via both canonical and non-canonical processes, downstream of cell surface activation. The non-canonical pathway results in expression of MAG, a specific transcription factor for the final differentiation of normal stem cells in the basal layer [45]. The canonical pathway activates MAML1-3, which are the main components involved in expression of the HEY/HES families. MAML1, 2, and 3 maintain the stem cell features of CSCs. Therefore, canonical and non-canonical pathways are involved in biology and preservation of CSCs and normal stem cells, respectively. We previously reported that NOTCH pathway is involved in progression and metastasis of ESCC [29, 46,47,48,49,50]. In the present study we selected MAML1 to target the NOTCH pathway only in CSCs with the activated canonical pathway with possibly no side effects to the normal stem cells in the basal layer. CD44+ ESCC-CSCs were isolated and identified as CSCs by in vivo and molecular methods. We showed that MAML1 silencing significantly reduced cell migration. On the other hand, MAML1 ectopic expression significantly increased the metastatic behavior of isolated CSCs. Moreover, cell cycle analysis showed that MAML1 silencing in CD44+ CSCs significantly increased the number of cells in G1 phase while ectopic expression significantly increased the number of cells in S phase. We observed a correlation between MAMl1 and TWIST1 expression in isolated cells which, agreed with our recent report from studies with ESCC patients [29]. Therefore, MAML1 exerts its role in cell migration via interaction with TWIST1. Furthermore, the drug assay showed that the MAML1 ectopically-expressed cells were more resistant to 5FU than the CD44+-CSCs. MAML1 silenced cells also had lower resistance than the intact CD44+-CSCs. Moreover, beside the NOTCH pathway we tested partially the role of WNT pathway in biology of isolated cells via the PYGO2 expressional analysis. Although this marker was assessed only in the level of mRNA expression and it needs further studies, it was shown that the WNT pathway probably has not a significant role in preservation of CD44+ CSCs. WNT pathway has the major role in chemo resistance of breast CSCs via the up regulation of MDR1 expression [51]. Therefore, it seems that in contrast with breast CSCs, MDR1 and WNT pathway is not involved in chemo resistance of ESCC-CSCs and such resistance is due to the NOTCH activation and ABC transporters.

Conclusion

We showed that the canonical NOTCH pathway in ESCC patients is one of the main factors in chemotherapeutic resistance. NOTCH pathway increases resistance toward 5FU in ESCC-CSCs using the activation of ABCG2. Therefore, targeted therapy against the canonical NOTCH pathway may be an efficient way to eliminate CSCs and decrease the rate of tumor recurrence without side effects for the normal stem cells in the basal layer.

Abbreviations

CSCs:

cancer stem cells

ESCC:

esophageal squamous cell carcinoma

EC:

esophageal cancer

EAC:

esophageal adenocarcinoma

nCRT:

neo adjuvant chemo-radiotherapy

ICN:

intracellular domain of NOTCH

MTT:

dimethyl thiazolyldiphenyl tetrazolium

References

  1. 1.

    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–50.

    PubMed  Article  Google Scholar 

  2. 2.

    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.

    PubMed  Article  Google Scholar 

  3. 3.

    van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.

    PubMed  Article  Google Scholar 

  4. 4.

    Smit JK, Pultrum BB, van Dullemen HM, Van Dam GM, Groen H, Plukker JT. Prognostic factors and patterns of recurrence in esophageal cancer assert arguments for extended two-field transthoracic esophagectomy. Am J Surg. 2010;200(4):446–53.

    PubMed  Article  Google Scholar 

  5. 5.

    Nguyen NP, Krafft SP, Vinh-Hung V, Vos P, Almeida F, Jang S, et al. Feasibility of tomotherapy to reduce normal lung and cardiac toxicity for distal esophageal cancer compared to three-dimensional radiotherapy. Radiother Oncol. 2011;101(3):438–42.

    PubMed  Article  Google Scholar 

  6. 6.

    Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012;488(7412):522–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest. 2010;120(1):41–50.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Moghbeli M, Moghbeli F, Forghanifard MM, Abbaszadegan MR. Cancer stem cell detection and isolation. Med Oncol. 2014;31(9):69.

    PubMed  Article  Google Scholar 

  9. 9.

    Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer. 2011;11(4):254–67.

    PubMed  Article  Google Scholar 

  10. 10.

    Zhao JS, Li WJ, Ge D, Zhang PJ, Li JJ, Lu CL, et al. Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS ONE. 2011;6(6):e21419.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Ishimoto T, Nagano O, Yae T, Tamada M, Motohara T, Oshima H, et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(−) and thereby promotes tumor growth. Cancer Cell. 2011;19(3):387–400.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, et al. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun. 2012;3:883.

    PubMed  Article  Google Scholar 

  13. 13.

    Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, et al. Notch-1 induces epithelial–mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011;307(1):26–36.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Chen C, Wei Y, Hummel M, Hoffmann TK, Gross M, Kaufmann AM, et al. Evidence for epithelial–mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS ONE. 2011;6(1):e16466.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity. 2010;32(1):14–27.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature. 2005;435(7044):964–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Rangarajan A, Talora C, Okuyama R, Nicolas M, Mammucari C, Oh H, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 2001;20(13):3427–36.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18.

    Taniguchi Y, Karlstrom H, Lundkvist J, Mizutani T, Otaka A, Vestling M, et al. Notch receptor cleavage depends on but is not directly executed by presenilins. Proc Natl Acad Sci USA. 2002;99(6):4014–9.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    Hsieh JJ, Zhou S, Chen L, Young DB, Hayward SD. CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci USA. 1999;96(1):23–8.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Kao HY, Ordentlich P, Koyano-Nakagawa N, Tang Z, Downes M, Kintner CR, et al. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev. 1998;12(15):2269–77.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Taniguchi Y, Furukawa T, Tun T, Han H, Honjo T. LIM protein KyoT2 negatively regulates transcription by association with the RBP-J DNA-binding protein. Mol Cell Biol. 1998;18(1):644–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Oswald F, Tauber B, Dobner T, Bourteele S, Kostezka U, Adler G, et al. p300 acts as a transcriptional coactivator for mammalian Notch-1. Mol Cell Biol. 2001;21(22):7761–74.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. 23.

    Wu L, Sun T, Kobayashi K, Gao P, Griffin JD. Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol. 2002;22(21):7688–700.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Jeffries S, Robbins DJ, Capobianco AJ. Characterization of a high-molecular-weight Notch complex in the nucleus of Notch(ic)-transformed RKE cells and in a human T-cell leukemia cell line. Mol Cell Biol. 2002;22(11):3927–41.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol. 2001;21(17):5925–34.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F, et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med. 2007;13(1):70–7.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci USA. 2006;103(48):18261–6.

    CAS  PubMed  Article  Google Scholar 

  28. 28.

    Niessen K, Fu Y, Chang L, Hoodless PA, McFadden D, Karsan A. Slug is a direct Notch target required for initiation of cardiac cushion cellularization. J Cell Biol. 2008;182(2):315–25.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Forghanifard MM, Moaven O, Farshchian M, Montazer M, Raeisossadati R, Abdollahi A, et al. Expression analysis elucidates the roles of MAML1 and Twist1 in esophageal squamous cell carcinoma aggressiveness and metastasis. Ann Surg Oncol. 2012;19(3):743–9.

    PubMed  Article  Google Scholar 

  30. 30.

    Abedi-Ardekani B, Sotoudeh M, Aghcheli K, Semnani S, Shakeri R, Taghavi N, et al. Esophagitis may not be a major precursor lesion for esophageal squamous cell carcinoma in a high incidence area in North-Eastern Iran. Middle East J Dig Dis. 2011;3(1):28–34.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Can Res. 2005;65(23):10946–51.

    CAS  Article  Google Scholar 

  32. 32.

    Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007;104(24):10158–63.

    CAS  Article  Google Scholar 

  33. 33.

    Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009;136(3):1012–24.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med. 1991;324(20):1385–93.

    PubMed  Article  Google Scholar 

  35. 35.

    Cooke G, Blanco-Fernandez A, Seery JP. The effect of retinoic acid and deoxycholic acid on the differentiation of primary human esophageal keratinocytes. Dig Dis Sci. 2008;53(11):2851–7.

    CAS  PubMed  Article  Google Scholar 

  36. 36.

    Shimizu M, Suzui M, Deguchi A, Lim JT, Weinstein IB. Effects of acyclic retinoid on growth, cell cycle control, epidermal growth factor receptor signaling, and gene expression in human squamous cell carcinoma cells. Clin Cancer Res. 2004;10(3):1130–40.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Mansouri A, Foroughmand AM, Abbaszadegan MR, Memar B, Mahmoudian RA, Gholamin M. Expression analysis of CD44 isoforms S and V3, in patients with esophageal squamous cell carcinoma. Iran J Basic Med Sci. 2015;18(4):380–4.

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Gotoda T, Matsumura Y, Kondo H, Ono H, Kanamoto A, Kato H, et al. Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma. Gut. 2000;46(1):14–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Roye GD, Myers RB, Brown D, Poczatek R, Beenken SW, Grizzle WE. CD44 expression in dysplastic epithelium and squamous-cell carcinoma of the esophagus. Int J Cancer. 1996;69(4):254–8.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Maraver A, Fernandez-Marcos PJ, Herranz D, Canamero M, Munoz-Martin M, Gomez-Lopez G, et al. Therapeutic effect of gamma-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. Cancer Cell. 2012;22(2):222–34.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Mizuma M, Rasheed ZA, Yabuuchi S, Omura N, Campbell NR, de Wilde RF, et al. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol Cancer Ther. 2012;11(9):1999–2009.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. 42.

    Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279(13):12876–82.

    CAS  Article  Google Scholar 

  43. 43.

    Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, et al. Therapeutic antibody targeting of individual Notch receptors. Nature. 2010;464(7291):1052–7.

    CAS  Article  Google Scholar 

  44. 44.

    Falk R, Falk A, Dyson MR, Melidoni AN, Parthiban K, Young JL, et al. Generation of anti-Notch antibodies and their application in blocking Notch signalling in neural stem cells. Methods. 2012;58(1):69–78.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Heitzler P, Simpson P. The choice of cell fate in the epidermis of Drosophila. Cell. 1991;64(6):1083–92.

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    Moghbeli M, Forghanifard MM, Aarabi A, Mansourian A, Abbaszadegan MR. Clinicopathological sex-related relevance of musashi1 mRNA expression in esophageal squamous cell carcinoma patients. Pathol Oncol Res. 2014;20(2):427–33.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Moghbeli M, Forghanifard MM, Sadrizadeh A, Mozaffari HM, Golmakani E, Abbaszadegan MR. Role of Msi1 and MAML1 in regulation of Notch signaling pathway in patients with esophageal squamous cell carcinoma. J Gastrointest Cancer. 2015;46(4):365–9.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Moghbeli M, Rad A, Farshchian M, Taghehchian N, Gholamin M, Abbaszadegan MR. Correlation between Meis1 and Msi1 in esophageal squamous cell carcinoma. J Gastrointest Cancer. 2016;47(3):273–7.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Moghbeli M, Sadrizadeh A, Forghanifard MM, Mozaffari HM, Golmakani E, Abbaszadegan MR. Role of Msi1 and PYGO2 in esophageal squamous cell carcinoma depth of invasion. J Cell Commun Signal. 2016;10(1):49–53.

    PubMed  Article  Google Scholar 

  50. 50.

    Taleb S, Abbaszadegan MR, Moghbeli M, Roudbari NH, Forghanifard MM. HES1 as an independent prognostic marker in esophageal squamous cell carcinoma. J Gastrointest Cancer. 2014;45(4):466–71.

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    Zhang ZM, Wu JF, Luo QC, Liu QF, Wu QW, Ye GD, et al. Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/beta-catenin pathway. Oncogene. 2016;35(36):4787–97.

    CAS  PubMed  Article  Google Scholar 

Download references

Authors’ contributions

MM, MMF, and MG were involved in experiments and drafting. HMM and BM were involved in tissue gathering and pathological assessments. MRA supervised the project. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Consent for publication

Informed consent form which was approved by the ethic committee of Mashhad University of Medical Sciences (#921202) was obtained from all individual participants included in the study.

Ethics approval and consent to participate

All procedures performed in study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Funding

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author information

Affiliations

  1. Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

    Meysam Moghbeli

  2. Gastroenterology and Hepatology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Hooman Mosannen Mozaffari

  3. Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Bahram Memar

  4. Department of Biology, Damghan Branch, Islamic Azad University, Damghan, Iran

    Mohammad Mahdi Forghanifard

  5. Department of Laboratory Sciences, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran

    Mehran Gholamin

  6. Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

    Mohammad Reza Abbaszadegan

Authors
  1. Meysam Moghbeli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hooman Mosannen Mozaffari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bahram Memar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mohammad Mahdi Forghanifard
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mehran Gholamin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mohammad Reza Abbaszadegan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammad Reza Abbaszadegan.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Moghbeli, M., Mosannen Mozaffari, H., Memar, B. et al. Role of MAML1 in targeted therapy against the esophageal cancer stem cells. J Transl Med 17, 126 (2019). https://doi.org/10.1186/s12967-019-1876-5

Download citation

Keywords

  • Cancer stem cell
  • CD44
  • ESCC
  • NOTCH pathway
  • MAML1
  • ABC transporter

Journal of Translational Medicine

ISSN: 1479-5876

Contact us